PMC:7402624 / 9759-10215 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T43","span":{"begin":261,"end":270},"obj":"Body_part"},{"id":"T44","span":{"begin":362,"end":396},"obj":"Body_part"},{"id":"T45","span":{"begin":391,"end":396},"obj":"Body_part"}],"attributes":[{"id":"A43","pred":"fma_id","subj":"T43","obj":"http://purl.org/sig/ont/fma/fma62852"},{"id":"A44","pred":"fma_id","subj":"T44","obj":"http://purl.org/sig/ont/fma/fma86713"},{"id":"A45","pred":"fma_id","subj":"T45","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"ween clinical measures of disease, inflammation, and co-morbidities (Fig. 1C and fig. S1C). Thus, COVID-19 patients presented with varied pre-existing comorbidities, complex clinical phenotypes, evidence of inflammation in many patients, and clinically altered leukocyte counts.\nTo begin to interrogate immune responses to acute SARS-CoV2 infection, we compared peripheral blood mononuclear cells (PBMC) of COVID-19 patients, RD, and HD subjects using high"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T6","span":{"begin":373,"end":378},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"ween clinical measures of disease, inflammation, and co-morbidities (Fig. 1C and fig. S1C). Thus, COVID-19 patients presented with varied pre-existing comorbidities, complex clinical phenotypes, evidence of inflammation in many patients, and clinically altered leukocyte counts.\nTo begin to interrogate immune responses to acute SARS-CoV2 infection, we compared peripheral blood mononuclear cells (PBMC) of COVID-19 patients, RD, and HD subjects using high"}

{"project":"LitCovid-PubTator","denotations":[{"id":"271","span":{"begin":107,"end":115},"obj":"Species"},{"id":"272","span":{"begin":228,"end":236},"obj":"Species"},{"id":"275","span":{"begin":35,"end":47},"obj":"Disease"},{"id":"276","span":{"begin":98,"end":106},"obj":"Disease"},{"id":"277","span":{"begin":207,"end":219},"obj":"Disease"},{"id":"305","span":{"begin":329,"end":338},"obj":"Species"},{"id":"306","span":{"begin":416,"end":424},"obj":"Species"},{"id":"309","span":{"begin":339,"end":348},"obj":"Disease"},{"id":"310","span":{"begin":407,"end":415},"obj":"Disease"},{"id":"311","span":{"begin":434,"end":436},"obj":"Disease"}],"attributes":[{"id":"A271","pred":"tao:has_database_id","subj":"271","obj":"Tax:9606"},{"id":"A272","pred":"tao:has_database_id","subj":"272","obj":"Tax:9606"},{"id":"A275","pred":"tao:has_database_id","subj":"275","obj":"MESH:D007249"},{"id":"A276","pred":"tao:has_database_id","subj":"276","obj":"MESH:C000657245"},{"id":"A277","pred":"tao:has_database_id","subj":"277","obj":"MESH:D007249"},{"id":"A305","pred":"tao:has_database_id","subj":"305","obj":"Tax:2697049"},{"id":"A306","pred":"tao:has_database_id","subj":"306","obj":"Tax:9606"},{"id":"A309","pred":"tao:has_database_id","subj":"309","obj":"MESH:D007239"},{"id":"A310","pred":"tao:has_database_id","subj":"310","obj":"MESH:C000657245"},{"id":"A311","pred":"tao:has_database_id","subj":"311","obj":"MESH:D006816"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ween clinical measures of disease, inflammation, and co-morbidities (Fig. 1C and fig. S1C). Thus, COVID-19 patients presented with varied pre-existing comorbidities, complex clinical phenotypes, evidence of inflammation in many patients, and clinically altered leukocyte counts.\nTo begin to interrogate immune responses to acute SARS-CoV2 infection, we compared peripheral blood mononuclear cells (PBMC) of COVID-19 patients, RD, and HD subjects using high"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T71","span":{"begin":35,"end":47},"obj":"Disease"},{"id":"T72","span":{"begin":98,"end":106},"obj":"Disease"},{"id":"T73","span":{"begin":207,"end":219},"obj":"Disease"},{"id":"T74","span":{"begin":329,"end":333},"obj":"Disease"},{"id":"T75","span":{"begin":339,"end":348},"obj":"Disease"},{"id":"T76","span":{"begin":407,"end":415},"obj":"Disease"},{"id":"T77","span":{"begin":426,"end":428},"obj":"Disease"},{"id":"T78","span":{"begin":434,"end":436},"obj":"Disease"}],"attributes":[{"id":"A71","pred":"mondo_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A72","pred":"mondo_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A73","pred":"mondo_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A74","pred":"mondo_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A75","pred":"mondo_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A76","pred":"mondo_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A77","pred":"mondo_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/MONDO_0009973"},{"id":"A78","pred":"mondo_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/MONDO_0007739"}],"text":"ween clinical measures of disease, inflammation, and co-morbidities (Fig. 1C and fig. S1C). Thus, COVID-19 patients presented with varied pre-existing comorbidities, complex clinical phenotypes, evidence of inflammation in many patients, and clinically altered leukocyte counts.\nTo begin to interrogate immune responses to acute SARS-CoV2 infection, we compared peripheral blood mononuclear cells (PBMC) of COVID-19 patients, RD, and HD subjects using high"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T98","span":{"begin":362,"end":396},"obj":"http://purl.obolibrary.org/obo/CL_0000842"},{"id":"T99","span":{"begin":362,"end":396},"obj":"http://purl.obolibrary.org/obo/CL_2000001"},{"id":"T100","span":{"begin":426,"end":428},"obj":"http://purl.obolibrary.org/obo/CLO_0008770"}],"text":"ween clinical measures of disease, inflammation, and co-morbidities (Fig. 1C and fig. S1C). Thus, COVID-19 patients presented with varied pre-existing comorbidities, complex clinical phenotypes, evidence of inflammation in many patients, and clinically altered leukocyte counts.\nTo begin to interrogate immune responses to acute SARS-CoV2 infection, we compared peripheral blood mononuclear cells (PBMC) of COVID-19 patients, RD, and HD subjects using high"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T31","span":{"begin":426,"end":428},"obj":"Chemical"},{"id":"T32","span":{"begin":434,"end":436},"obj":"Chemical"}],"attributes":[{"id":"A31","pred":"chebi_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_73812"},{"id":"A32","pred":"chebi_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/CHEBI_73925"}],"text":"ween clinical measures of disease, inflammation, and co-morbidities (Fig. 1C and fig. S1C). Thus, COVID-19 patients presented with varied pre-existing comorbidities, complex clinical phenotypes, evidence of inflammation in many patients, and clinically altered leukocyte counts.\nTo begin to interrogate immune responses to acute SARS-CoV2 infection, we compared peripheral blood mononuclear cells (PBMC) of COVID-19 patients, RD, and HD subjects using high"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T25","span":{"begin":35,"end":47},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T26","span":{"begin":207,"end":219},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T27","span":{"begin":303,"end":319},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"ween clinical measures of disease, inflammation, and co-morbidities (Fig. 1C and fig. S1C). Thus, COVID-19 patients presented with varied pre-existing comorbidities, complex clinical phenotypes, evidence of inflammation in many patients, and clinically altered leukocyte counts.\nTo begin to interrogate immune responses to acute SARS-CoV2 infection, we compared peripheral blood mononuclear cells (PBMC) of COVID-19 patients, RD, and HD subjects using high"}

{"project":"LitCovid-sentences","denotations":[{"id":"T68","span":{"begin":92,"end":278},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ween clinical measures of disease, inflammation, and co-morbidities (Fig. 1C and fig. S1C). Thus, COVID-19 patients presented with varied pre-existing comorbidities, complex clinical phenotypes, evidence of inflammation in many patients, and clinically altered leukocyte counts.\nTo begin to interrogate immune responses to acute SARS-CoV2 infection, we compared peripheral blood mononuclear cells (PBMC) of COVID-19 patients, RD, and HD subjects using high"}